All attention has been on biosimilar policy, infliximab and to a lesser extent insulin glargine, but the issue is moving so quickly it is hard to imagine the focus will not shift elsewhere - sooner rather than later. …
Latest Video
New Stories
-
Senate backs order for the production of documents on submission deferrals
November 27, 2024 - - Latest News -
Outgoing President proposes dramatic expansion in funded access to anti-obesity therapies
November 27, 2024 - - Latest News -
Whooping cough cases surge across Australia as vaccination rates fall
November 27, 2024 - - Latest News -
Australian-backed triple-combination hypertension treatment proceeding to regulatory submission
November 27, 2024 - - Latest News -
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 - - Australian Biotech -
Medical cannabis company Montu appoints experienced industry executive to key policy and advocacy role
November 27, 2024 - - Latest News -
Island Pharmaceuticals says ISLA-101 shows anti-dengue activity in Phase 2a study readout
November 27, 2024 - - Australian Biotech